Abstract
Raltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles were given (median two, range one to four). The drug was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in only one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive as second line therapy for small-cell lung cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clarke S. J., Hanwell J., de Boer M., Planting A., Verweij J., Walker M., Smith R., Jackman A. L., Hughes L. R., Harrap K. R. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol. 1996 May;14(5):1495–1503. doi: 10.1200/JCO.1996.14.5.1495. [DOI] [PubMed] [Google Scholar]
- Cunningham D., Zalcberg J. R., Rath U., Olver I., Van Cutsem E., Svensson C., Seitz J. F., Harper P., Kerr D., Perez-Manga G. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer. 1995 Nov;31A(12):1945–1954. doi: 10.1016/0959-8049(95)00502-1. [DOI] [PubMed] [Google Scholar]
- Cunningham D., Zalcberg J., Smith I., Gore M., Pazdur R., Burris H., 3rd, Meropol N. J., Kennealey G., Seymour L. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Ann Oncol. 1996 Feb;7(2):179–182. doi: 10.1093/oxfordjournals.annonc.a010546. [DOI] [PubMed] [Google Scholar]
- Ettinger D. S. Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come. J Clin Oncol. 1990 Mar;8(3):374–377. doi: 10.1200/JCO.1990.8.3.374. [DOI] [PubMed] [Google Scholar]
- Jackman A. L., Taylor G. A., Gibson W., Kimbell R., Brown M., Calvert A. H., Judson I. R., Hughes L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991 Oct 15;51(20):5579–5586. [PubMed] [Google Scholar]
- Moore T. D., Korn E. L. Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst. 1992 Feb 5;84(3):150–154. doi: 10.1093/jnci/84.3.150. [DOI] [PubMed] [Google Scholar]
- Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]